Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 30Expanded_access 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

3-Iodobenzylguanidine 6Magnetic Resonance Spectroscopy 5Amifampridine 5gallium 68 PSMA-11 4fludarabine phosphate 3Cyclophosphamide 3pembrolizumab 2fluorodopa F 18 2fludarabine 2carbon-11 acetate 2Whole-Body Irradiation 2Oxaliplatin 2Ga(III)-DOTATOC 2Fluorouracil 2Bortezomib 2Bone Marrow Transplantation 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2venetoclax 1veliparib 1ulocuplumab 1trametinib 1selinexor 1ponatinib 1pegfilgrastim 1omburtamab I-131 1nirogacestat 1neratinib 1navitoclax 1motexafin gadolinium 1mifamurtide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Expanded_access × elotuzumab × Clear all
NCT02541643 2015-09-04

Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

Icahn School of Medicine at Mount Sinai

No longer available
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡